LBCTR2019080232已完成3 期
A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment
ovartis Pharma Services Inc.0 个研究点目标入组 6 人开始时间: 2023年9月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 至 99（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •1.Patient is an adult male/female = 18 years old at the time of informed consent and has signed informed consent before any trial related activities and according to local guidelines. Female patients must be postmenopausal.
- •2.Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer.
- •3.Patient must have either measurable disease by RECIST 1.1 or at least one predominantly lytic bone lesion.
- •4.Patient has advanced (loco regionally recurrent not amenable to curative therapy, e.g. surgery and/or radiotherapy, or metastatic) breast cancer.
- •Patients may be:
- •?newly diagnosed advanced/metastatic breast cancer, treatment naïve
- •?relapsed with documented evidence of relapse more than 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for advanced/metastatic disease
- •?relapsed with documented evidence of relapse on or within 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for advanced/metastatic disease
- •?relapsed with documented evidence of relapse more than 12 months from completion of adjuvant endocrine therapy and then subsequently progressed with documented evidence of progression after one line of endocrine therapy (with either an antiestrogen or an aromatase inhibitor) for advanced/metastatic disease
- •?newly diagnosed advanced/metastatic breast cancer at diagnosis that progressed with documented evidence of progression after one line of endocrine therapy (with either an antiestrogen or an aromatase inhibitor)
- •5.Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •6.Patient has adequate bone marrow and organ function
排除标准
- •Exclusion Criteria:
- •1.Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment.
- •2.Patient has received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant or any CDK4/6 inhibitor.
- •3.Patient with inflammatory breast cancer at screening .
- •4.Patient with CNS involvement unless they are at least 4 weeks from prior therapy completion to starting the study treatment and have stable CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases
- •5.Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality
- •6.Patient is currently receiving any of the following substances and cannot be discontinued 7 days prior to start the treatment:
- •?Known strong inducers or inhibitors of CYP3A4/5,
- •?That have a known risk to prolong the QT interval or induce Torsades de Pointes.
- •?Those have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
- •?Herbal preparations/medications, dietary supplements.
研究者
相似试验
已完成
3 期
Efficacy of Hair Serum Containing Solid Lipid Nanoparticle Loaded Acanthus ebracteatusThe healthy male volunteers have baldness or abnormal hair fall problem.Hair fallBaldnessTCTR20240318001aresuan University72
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2019-004941-34-ITGENFIT150
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 100000004871Primary Biliary CholangitisEUCTR2019-004941-34-FRGENFIT150
招募中
3 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidPrimary Biliary Cholangitis2024-512232-30-00Ipsen Pharma61
进行中（未招募）
1 期
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic AcidMedDRA version: 21.0Level: LLTClassification code 10034176Term: PBCSystem Organ Class: 10019805 - Hepatobiliary disordersPrimary Biliary CholangitisEUCTR2019-004941-34-DEIPSEN Pharma SAS161